Worth, Heinrich
Criée, Carl-Peter
Vogelmeier, Claus F.
Kardos, Peter
Becker, Eva-Maria
Kostev, Karel
Mokros, Ingo
Schneider, Andrea
Funding for this research was provided by:
AstraZeneca
Article History
Received: 11 September 2020
Accepted: 31 March 2021
First Online: 16 April 2021
Declarations
:
: German law allows the use of anonymous electronic medical records for research purposes under certain conditions. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data. Because patients were only queried as aggregates and no protected health information was available for queries, no institutional review board approval was required for the use of this database or the completion of this study.
: Not applicable.
: IM and AS are employees of AstraZeneca. E-MB and KK are employees of IQVIA. PK reports personal fees from Novartis, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Menarini, and Takeda, all of which are outside the submitted work. CFV reports personal fees from Almirall, Cipla, Berlin-Chemie/Menarini, CSL Behring, and Teva, grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Grifols, Mundipharma, Novartis, and Takeda, and grants from the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (AsCoNet), Bayer Schering Pharma AG, MSD, and Pfizer, all of which are outside the submitted work. HW reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Klosterfrau, Menarini, Novartis, Omron, and Takeda, all of which are outside the submitted work. C-PC reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Klosterfrau, Menarini, Novartis, Omron, Sanofi, and Takeda, all of which are outside the submitted work.